New pancreatic cancer drug regimen shows 'impressive' results in clinical trial
The Parker Institute for Cancer Immunotherapy, funded by Napster founder and billionaire Sean Parker, on Sunday presented the results of clinical trials testing a new treatment for metastatic pancreatic cancer. The results, presented at the annual meeting of the American Association of Cancer Research in Atlanta, Georgia, came just a year and a half after the first patient was enrolled in the trial — "moving fast" by pharmaceutical standards, said Ramy Ibrahim, the Parker Institute's chief medical officer.
The findings show partial tumor shrinkage in metastatic pancreatic cancer patients who'd had no cancer treatment before the multi-drug regimen the trial was testing, Stat News reported Monday. Pancreatic cancer is the third deadliest type of cancer, which makes these early findings "impressive," said the investigator in charge of the trial, Robert Vonderheide.
In addition to the standard drugs typically prescribed for pancreatic cancer, patients were given a third drug, an "experimental antibody" called APX005M. And half of the patients in the trial were also given a fourth drug: Optivo, typically prescribed for lung cancer patients. Patients who received all four drugs had the best results, with 54 percent of them seeing tumor shrinkage that lasted up to 10 months or more.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
With the Phase 1 trial complete, this new regimen will undergo further testing from the Parker Institute before it can move ahead to potentially become a viable treatment for pancreatic cancer patients. Read more about the trial results at Stat News.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Shivani is the editorial assistant at TheWeek.com and has previously written for StreetEasy and Mic.com. A graduate of the physics and journalism departments at NYU, Shivani currently lives in Brooklyn and spends free time cooking, watching TV, and taking too many selfies.
-
'Make legal immigration a more plausible option'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
LA-to-Las Vegas high-speed rail line breaks ground
Speed Read The railway will be ready as soon as 2028
By Peter Weber, The Week US Published
-
Israel's military intelligence chief resigns
Speed Read Maj. Gen. Aharon Haliva is the first leader to quit for failing to prevent the Hamas attack in October
By Justin Klawans, The Week US Published
-
Puffed rice and yoga: inside the collapsed tunnel where Indian workers await rescue
Speed Read Workers trapped in collapsed tunnel are suffering from dysentery and anxiety over their rescue
By Sorcha Bradley, The Week UK Published
-
More than 2,000 dead following massive earthquake in Morocco
Speed Read
By Justin Klawans Published
-
Mexico's next president will almost certainly be its 1st female president
Speed Read
By Peter Weber Published
-
North Korea's Kim to visit Putin in eastern Russia to discuss arms sales for Ukraine war, U.S. says
Speed Read
By Peter Weber Published
-
Gabon's military leader sworn in following coup in latest African uprising
Speed Read
By Justin Klawans Published
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
By Peter Weber Published
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
By Justin Klawans Published
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
By Peter Weber Published